A section of Journal of Personalized Medicine (ISSN 2075-4426).
The section of pharmacogenetics of the Journal of Personalized Medicine is open to receive high-quality research and review articles, as well as short communications on all aspects of pharmacogenetics (from gene to the clinic) for rapid publication. Interests are focused on the effects of genotype on the pharmacology of drugs in all therapeutic areas, leading to personalized treatments.
Key areas of coverage include:
- Effects of genetic variability on drug toxicity and efficacy;
- Identification and functional characterization of polymorphisms relevant to drug action;
- Integration of new developments in the genome project into clinical pharmacology, therapeutics, and medicine;
- Clinical implementation of pharmacogenetics;
- Identification of novel genomics targets for drug development;
- Companion diagnostics and drug development.
The section combines articles from the entire range of biomedical research and science, including clinical pharmacology, clinical pharmacy, genetics, genomics, molecular biology, pharmacology and toxicology, biochemistry, epidemiology, and bioinformatics.
Topical Advisory Panel
Following special issues within this section are currently open for submissions:
- Pharmacogenomics from Research to Clinical Implementation (Deadline: 10 October 2023)
- Genetics, Genomics, and Precision Medicine in Colorectal Cancer (Deadline: 20 October 2023)
- Pharmacogenomics: Current Status and Future Perspectives (Deadline: 5 February 2024)
- COVID-19 Medicines in Pharmacogenomics (Deadline: 20 February 2024)
- Drug-Drug-Gene Interactions and Adverse Drug Reactions (Deadline: 1 March 2024)
- Pharmacogenomics and Hypertension: Problems and Prospects (Deadline: 25 March 2024)